Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAFIK ABADIER

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1649253147
CMS profile
256213
Location
INVERNESS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$222.26

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $222.26 5

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAFIK ABADIER

NPI 1649253147 · CMS profile ID 256213

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

INVERNESS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649253147?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649253147?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649253147?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1649253147?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $222.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $17.5010/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200009464 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $30.0909/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222864406 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.8806/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222864402 CMS
Boston Scientific Corporation $126.9103/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181379088 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.8802/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222864398 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,012.13 30
PY2020 $285.07 11
PY2021 $127.23 4
PY2022 $153.51 10
PY2023 $3,321.33 24
PY2024 $2,191.02 22
PY2025 $222.26 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $731.79 4
PY2025 Principal investigator $554,369.24 96
PY2024 Principal investigator $1,358,878.08 258
PY2023 Principal investigator $1,095,651.17 1,020
PY2022 Principal investigator $767,493.58 1,505
PY2021 Principal investigator $331,251.89 220
PY2020 Principal investigator $152,753.28 147
PY2019 Principal investigator $85,046.12 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

220 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423483
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423491
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,225.13 12/31/2021 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
Title not available ETESIAN Cardiovascular, Renal and Metabolism CV, Product AZD8233 No dispute reported 06/30/2026 826467719
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,515.96 12/31/2021 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
Randomised Parallel Double Blind Placebo Controlled Phase 2b Study to Assess the Safety Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia SOLANO No dispute reported 06/30/2026 826504507
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/16/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838453991
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/16/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838453999
Principal investigator 1 Esperion Therapeutics, Inc. $32.40 12/16/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838454007
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 12/10/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH INVERNESS
A Phase2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia No dispute reported 06/30/2026 848740355
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/02/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838452127
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/02/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838452135
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/02/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838452143
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/02/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838452151
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/02/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838452159
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/02/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838452167
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 12/02/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838452174
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 12/02/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838452181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,921.70 12/01/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $440.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $105.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $440.00 11/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,194.80 11/05/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423239
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445749
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445757
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445765
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445773
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445781
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445787
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445795
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445803
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445811
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445819
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445825
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 10/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838445835
Principal investigator 1 Boehringer Ingelheim International GmbH $10,040.15 10/05/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 09/24/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,450.00 09/24/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423295
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 09/24/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423297
Principal investigator 1 Boehringer Ingelheim International GmbH $397.00 09/23/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338379
Principal investigator 1 Boehringer Ingelheim International GmbH $912.30 09/23/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423159
Principal investigator 1 Esperion Therapeutics, Inc. $1,241.00 08/24/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838432145
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 08/24/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838432153
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 08/24/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838432161
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 08/24/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838432169
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 08/24/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838432175
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 08/24/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838432185
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 08/24/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838432191
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 08/24/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838432199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423199
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 07/20/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838423719
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 07/20/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838423725
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 07/20/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838423733
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 07/20/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838423741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 07/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 07/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 07/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 07/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 07/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423139
Principal investigator 1 AstraZeneca Pharmaceuticals LP $49,248.99 07/16/2021 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
Randomised Parallel Double Blind Placebo Controlled Phase 2b Study to Assess the Safety Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia SOLANO No dispute reported 06/30/2026 826479765
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,354.05 07/07/2021 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
Cardiovascular Renal and Metabolism Dyslipidaemia No dispute reported 06/30/2026 826461761
Principal investigator 1 Boehringer Ingelheim International GmbH $842.00 07/01/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338383
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 06/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838418583
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 06/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838418591
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 06/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838418599
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 06/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838418607
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 06/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838418615
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 06/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838418623
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415761
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415769
Principal investigator 1 Esperion Therapeutics, Inc. $32.40 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415777
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415785
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415791
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415799
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415806
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415813
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415821
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415829
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 06/01/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838415835
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,282.63 05/21/2021 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
An Observational Non interventional Study in Hyperlipidaemic Patients on Lipid Lowering Therapy OSTRO No dispute reported 06/30/2026 826462679
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 04/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406983
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 04/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406991
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 04/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406997
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 04/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838407003
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 04/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838407011
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 04/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838407019
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 04/22/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838407027
Principal investigator 1 Boehringer Ingelheim International GmbH $818.00 04/08/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338387
Principal investigator 1 Boehringer Ingelheim International GmbH $818.00 04/08/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338389
Principal investigator 1 Boehringer Ingelheim International GmbH $818.00 04/08/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338391
Principal investigator 1 Boehringer Ingelheim International GmbH $818.00 04/08/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338393
Principal investigator 1 Boehringer Ingelheim International GmbH $818.00 04/08/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338395
Principal investigator 1 Boehringer Ingelheim International GmbH $818.00 04/08/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338397
Principal investigator 1 Boehringer Ingelheim International GmbH $818.00 04/08/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338399
Principal investigator 1 Boehringer Ingelheim International GmbH $818.00 04/08/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338401
Principal investigator 1 Boehringer Ingelheim International GmbH $818.00 04/08/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338403
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 03/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838401787
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 03/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838401795
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 03/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838401803
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 03/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838401811
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 03/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838401817
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 03/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838401833
Principal investigator 1 Boehringer Ingelheim International GmbH $1,102.00 03/09/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338375
Principal investigator 1 Boehringer Ingelheim International GmbH $1,102.00 03/09/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338411
Principal investigator 1 Boehringer Ingelheim International GmbH $1,102.00 03/09/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338413
Principal investigator 1 Boehringer Ingelheim International GmbH $1,102.00 03/09/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338415
Principal investigator 1 Boehringer Ingelheim International GmbH $1,102.00 03/09/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338417
Principal investigator 1 Boehringer Ingelheim International GmbH $1,102.00 03/09/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338419
Principal investigator 1 Boehringer Ingelheim International GmbH $1,102.00 03/09/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338421
Principal investigator 1 Boehringer Ingelheim International GmbH $1,102.00 03/09/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338423
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 02/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838396967
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 02/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838396976
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 02/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838396983
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 02/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838396991
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 02/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838396999
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 02/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838397007
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 02/23/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838397013
Principal investigator 1 Boehringer Ingelheim International GmbH $240.00 02/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338425
Principal investigator 1 AstraZeneca Pharmaceuticals LP $115,748.80 02/09/2021 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
Title not available ETESIAN Cardiovascular, Renal and Metabolism CV, Product AZD8233 No dispute reported 06/30/2026 826496307
Principal investigator 1 Boehringer Ingelheim International GmbH $59.95 02/02/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338377
Principal investigator 1 Boehringer Ingelheim International GmbH $32.41 02/02/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338385
Principal investigator 1 Boehringer Ingelheim International GmbH $130.34 02/02/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338407
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 01/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390153
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 01/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390161
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 01/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390169
Principal investigator 1 Esperion Therapeutics, Inc. $605.00 01/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390179
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 01/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390187
Principal investigator 1 Esperion Therapeutics, Inc. $231.00 01/26/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390193
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 01/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338371
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 01/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338373
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 01/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338427
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 01/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338429
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 01/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338431
Principal investigator 1 Boehringer Ingelheim International GmbH $1,002.00 01/19/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338433
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,846.44 01/11/2021 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A MULTICENTER RANDOMIZED DOUBLE BLIND ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFECTS OF LCZ696 COMPARED TO VALSARTAN ON COGNITIVE FUNCTION AS ASSESSED BY COMPREHENSIVE NEUROCOGNITIVE BATTERY AND BRAIN AMYLOID PLAQUE DEPOSITION AS ASSESSED BY PET IMAGING IN PATIENTS WITH CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION No dispute reported 06/30/2026 800637135
Principal investigator 1 Boehringer Ingelheim International GmbH $102.22 01/05/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338405
Principal investigator 1 Boehringer Ingelheim International GmbH $102.22 01/05/2021 Non-covered Recipient Entity
Nature Coast Clinical Research
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 828338409